{"id":116,"date":"2026-07-15T05:19:48","date_gmt":"2026-07-15T05:19:48","guid":{"rendered":"https:\/\/dentaltransitions.sites.aigrowthagent.co\/dental-practice-ebitda-valuation-2026\/"},"modified":"2026-07-15T05:19:48","modified_gmt":"2026-07-15T05:19:48","slug":"dental-practice-ebitda-valuation-2026","status":"publish","type":"post","link":"https:\/\/dentaltransitions.com\/articles\/dental-practice-ebitda-valuation-2026\/","title":{"rendered":"Dental Practice EBITDA Valuation: Multiples Explained"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li>\n<p>Practice value equals normalized EBITDA multiplied by the market multiple. Defensible EBITDA is the single biggest driver of sale price.<\/p>\n<\/li>\n<li>\n<p>Normalized EBITDA adjusts reported net income by adding back owner compensation above market rates, personal expenses, and one-time costs. This reflects true transferable earnings under new ownership.<\/p>\n<\/li>\n<li>\n<p>McLerran&#8217;s CPA-led process documents every add-back with invoices, compensation benchmarks, and lease comparables, so the figure can hold up under a buyer&#8217;s Quality of Earnings review.<\/p>\n<\/li>\n<li>\n<p>Well-run general practices in 2026 can achieve normalized EBITDA margins in the 18-28% range. Hygiene mix and associate coverage tend to be the main levers that move a practice within that range.<\/p>\n<\/li>\n<li>\n<p>Owners who want to understand what their normalized EBITDA could be worth can <a target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https:\/\/dentaltransitions.com\/contact-us\/\">schedule a free, confidential discovery call with McLerran<\/a> to model both DSO and private-buyer outcomes.<\/p>\n<\/li>\n<\/ul>\n<h2>The Core Valuation Formula: EBITDA Times Multiple<\/h2>\n<p>The formula below shows how each piece works for a $2M revenue general dental practice in 2026.<\/p>\n<table style=\"min-width: 75px;\">\n<colgroup>\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\"><\/colgroup>\n<tbody>\n<tr>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Component<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Definition<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>2026 Example<\/p>\n<\/th>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Normalized EBITDA<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Adjusted earnings before interest, taxes, depreciation, and amortization. Owner compensation is reset to market rate and personal or one-time expenses are removed.<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>$400,000 (20% margin on $2M collections)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Market Multiple<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>The amount buyers pay per dollar of normalized EBITDA, based on practice size, hygiene mix, associate coverage, and buyer type.<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>6x-7x <a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/privatepracticeresearch.org\/reports\/how-dental-practices-are-valued-2026\">for a DSO add-on buyer<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Indicated Enterprise Value<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>The resulting valuation before deal-structure adjustments.<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p><a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/privatepracticeresearch.org\/reports\/how-dental-practices-are-valued-2026\">$2.4M-$2.8M for a DSO buyer<\/a><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Small changes in normalized EBITDA can produce large changes in enterprise value. A $100,000 change in normalized EBITDA at a 6x-8x multiple shifts practice valuation by $600,000 to $800,000. That is why the quality of the underlying analysis matters so much, and it sets up the question of how normalized EBITDA gets calculated in the first place.<\/p>\n<h2>What Normalized EBITDA Actually Measures<\/h2>\n<p>Reported net income on a dental practice tax return is designed to minimize taxable income. It does not reflect the practice&#8217;s true earning power under new ownership. Normalized EBITDA corrects for that gap. It starts with net income, adds back interest, taxes, depreciation, and amortization, then adjusts for owner-specific compensation, personal expenses, and non-recurring costs.<\/p>\n<p>Buyers use normalized EBITDA instead of reported net income to answer one question: how much profit would this practice generate under different ownership? That means adding back personal or one-time expenses and subtracting a clinical replacement cost, typically around 30-35% of the owner&#8217;s production, to reflect what a hired associate would cost.<\/p>\n<p>DSO and private equity buyers apply EBITDA multiples to this normalized figure. Private buyers, meaning individual dentists, more often underwrite on Seller&#8217;s Discretionary Earnings (SDE), a related but different metric that includes the full owner compensation package. They may also reference a percentage of collections. Knowing which metric applies to which buyer type matters when the calculation moves from formula to practice.<\/p>\n<h2>The Step-by-Step Path from Net Income to Normalized EBITDA<\/h2>\n<p>McLerran &amp; Associates builds every valuation from the ground up using a CPA-led methodology. The firm remotely accesses the practice&#8217;s management software, pulls production and collections reports, and cross-references that data against tax returns and financial statements. The normalization process follows these steps:<\/p>\n<ol>\n<li>\n<p><strong>Start with reported net income<\/strong> from the practice&#8217;s most recent tax return or profit-and-loss statement.<\/p>\n<\/li>\n<li>\n<p><strong>Add back ITDA<\/strong>, meaning Interest, Taxes, Depreciation, and Amortization, to arrive at base EBITDA.<\/p>\n<\/li>\n<li>\n<p><strong>Normalize owner compensation<\/strong> by replacing the owner&#8217;s actual pay with a market-rate replacement-doctor cost, usually expressed as a percentage of clinical production.<\/p>\n<\/li>\n<li>\n<p><strong>Add back personal and discretionary expenses<\/strong> run through the practice, such as vehicles, travel, and club memberships.<\/p>\n<\/li>\n<li>\n<p><strong>Add back one-time and non-recurring costs<\/strong>, including legal settlements, emergency equipment repairs, and one-time consulting fees.<\/p>\n<\/li>\n<li>\n<p><strong>Apply negative adjustments<\/strong> where needed, for example if owner compensation runs below market or deferred maintenance will require near-term capital investment.<\/p>\n<\/li>\n<li>\n<p><strong>Restate revenue to net collections<\/strong> when the practice reports production-based UCR revenue with separate insurance adjustments, so buyers can compare apples to apples.<\/p>\n<\/li>\n<\/ol>\n<p>Every add-back faces scrutiny during buyer due diligence. McLerran documents each adjustment with supporting evidence before the practice goes to market. That upfront work is what keeps the agreed value from being renegotiated later.<\/p>\n<p><a target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https:\/\/dentaltransitions.com\/contact-us\/\"><strong>See what your normalized EBITDA could look like<\/strong> with a free, confidential discovery call with McLerran &amp; Associates.<\/a><\/p>\n<h2>Which Add-Backs Hold Up and Which Get Rejected<\/h2>\n<p>The table below covers the most common add-back categories McLerran encounters, the documentation standard the firm applies, and the typical valuation impact on a $1.5M-$3M practice.<\/p>\n<table style=\"min-width: 100px;\">\n<colgroup>\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\"><\/colgroup>\n<tbody>\n<tr>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Add-Back Category<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Common Examples<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>McLerran Documentation Standard<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Typical Impact on $1.5M-$3M Practice<\/p>\n<\/th>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Owner Compensation Normalization<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Owner W-2 above market-rate replacement-doctor cost<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Market compensation analysis comparing owner production to regional associate pay benchmarks<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p><a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/thesorso.com\/answers\/ebitda-add-backs-practice-valuation\">$100,000-$400,000 per owner<\/a>, the most contested add-back in buyer QoE review<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Personal &amp; Discretionary Expenses<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Personal vehicles, club memberships, owner travel, personal cell phone, meals benefiting the owner<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Line-by-line P&amp;L review with receipts and business-purpose documentation<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>$15,000-$80,000 after stripping non-business items<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Family Member Payroll<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Spouse or family member paid above market rate for their role<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Job description, hours worked, and market-rate comparison<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>$30,000-$150,000; only the above-market portion qualifies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>One-Time &amp; Non-Recurring Costs<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Emergency equipment replacement, litigation settlements, EHR implementation<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Invoices, legal documents, or vendor contracts confirming non-recurring nature<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p><a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/thesorso.com\/answers\/ebitda-add-backs-practice-valuation\">$20,000-$100,000+<\/a> depending on the event<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Related-Party Rent Adjustment<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Above- or below-market rent paid to an entity the owner controls<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Independent lease comparable analysis<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>+\/- $25,000-$120,000 depending on deviation from market rates<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Buyers routinely reject certain add-backs: cash payments not recorded on the books, personal residence costs paid by the practice, and coaching engagements tied to the owner&#8217;s personal development rather than practice growth. These rejections happen because they cannot be traced to documentation, and aggressive add-backs that fail buyer diligence can undermine credibility on every other adjustment in the file. That risk is exactly why McLerran applies a conservative standard and documents each item before going to market.<\/p>\n<h2>Setting a Realistic EBITDA Margin Target<\/h2>\n<p><a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/thesorso.com\/answers\/dental-practice-ebitda-multiple\">Normalized EBITDA margins for dental practices typically run 18-28% after adjusting owner compensation to market rates<\/a>. Practices at the lower end are generally well-run but have room to improve. Practices above 25% tend to attract competitive bidding from institutional buyers.<\/p>\n<p>Two operational factors can meaningfully shift where a practice lands within that range.<\/p>\n<ul>\n<li>\n<p><strong>Hygiene production mix.<\/strong> Practices where hygiene revenue makes up about 25-35% or more of total collections consistently get better valuation offers because recurring hygiene visits signal a stable, transferable patient base. Hygiene revenue above 30% of collections can support a 0.5x to 1.0x multiple premium from DSO buyers.<\/p>\n<\/li>\n<li>\n<p><strong>Associate coverage.<\/strong> Practices where the owner-doctor performs 90% or more of production can face a 10-20% valuation reduction because DSO buyers cannot underwrite production that leaves with the seller. Each additional producing associate can reduce key-person risk and support a higher multiple.<\/p>\n<\/li>\n<\/ul>\n<h2>How Multiples Vary by Practice Size and Buyer Type<\/h2>\n<p>Multiple ranges vary widely by practice profile, drawing on data from FOCUS Investment Banking, Sorso, Auxo Capital Advisors, and Dental Pitch Brokerage. These are ranges, not guarantees. The specific multiple a practice achieves depends on its individual fundamentals and the competitive dynamics of the sale process.<\/p>\n<table style=\"min-width: 100px;\">\n<colgroup>\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\"><\/colgroup>\n<tbody>\n<tr>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Practice Profile<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Typical Multiple Range (2026)<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Buyer Type<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Key Value Drivers<\/p>\n<\/th>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Single-location, owner-dependent, under $1M EBITDA<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p><a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/thesorso.com\/answers\/dental-practice-ebitda-multiple\">5x-7x normalized EBITDA<\/a><\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Independent buyer or small DSO tuck-in<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Active patient count, hygiene mix, lease terms, payer mix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Single-location with associate coverage, $1M-$3M EBITDA<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>6x-9x normalized EBITDA<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Regional DSO add-on buyer<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Associate continuity, hygiene above 30% of collections, commercial payer mix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Multi-location group, $3M-$5M EBITDA<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p><a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/thesorso.com\/answers\/dental-practice-ebitda-multiple\">9x-11x normalized EBITDA<\/a><\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Emerging platform or strategic acquirer<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Management depth, clean reporting, durable collections<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Platform-grade group, $5M+ EBITDA<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p><a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/thesorso.com\/answers\/dental-practice-ebitda-multiple\">10x-12x+ normalized EBITDA<\/a><\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>PE-backed DSO platform buyer<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Scale, multi-state footprint, institutional-grade reporting<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For owners of $1.5M-$3M revenue practices, the multiple within the 6x-9x add-on tier band still varies a lot. The spread, potentially $4.5M to $6.75M in enterprise value on the same EBITDA figure, comes down to a few specific factors:<\/p>\n<ul>\n<li>\n<p>Whether the practice has producing associate coverage that reduces owner dependency<\/p>\n<\/li>\n<li>\n<p>Hygiene production as a percentage of total collections<\/p>\n<\/li>\n<li>\n<p>Commercial PPO payer mix versus Medicaid concentration<\/p>\n<\/li>\n<li>\n<p>Geographic market and DSO cluster fit<\/p>\n<\/li>\n<li>\n<p>Quality and completeness of financial reporting<\/p>\n<\/li>\n<\/ul>\n<p>Valuation multiples matter most when tied to transferable EBITDA, not treated as a static market headline. A practice with $800,000 of well-documented, transferable normalized EBITDA at a 6x multiple produces a stronger outcome than a practice with $400,000 of contested EBITDA at a 9x multiple. The quality of the underlying earnings figure matters as much as the multiple applied to it. This is also why specialty practices need their own read: multiple ranges for specialties vary by size, payer mix, and referral network dynamics, and McLerran&#8217;s dental-only focus means the firm evaluates each specialty on its own terms rather than a one-size-fits-all framework.<\/p>\n<h2>Why Buyers Scrutinize Every Add-Back Before Closing<\/h2>\n<p>Documentation quality determines what happens next: a buyer&#8217;s financial team will run a Quality of Earnings (QoE) review, testing every add-back, reconciling collections data, reviewing AR aging, and probing for unsupported adjustments. For sellers without diligence-grade preparation, this is where deals get re-traded or collapse entirely.<\/p>\n<p>McLerran&#8217;s CPA-led process is built to prevent that outcome.<\/p>\n<ul>\n<li>\n<p><strong>Remote software access.<\/strong> McLerran pulls production and collections reports directly from the practice management system, cross-referencing against tax returns to catch discrepancies before a buyer does.<\/p>\n<\/li>\n<li>\n<p><strong>Add-back documentation.<\/strong> Every normalization adjustment is backed by invoices, compensation analyses, lease comparables, or other primary documentation, not narrative claims.<\/p>\n<\/li>\n<li>\n<p><strong>Buyer QoE rebuttal.<\/strong> When a buyer&#8217;s QoE team challenges an add-back, McLerran defends the position with the underlying documentation. <a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/thesorso.com\/answers\/ebitda-add-backs-practice-valuation\">Buyers typically accept 70-90% of seller-proposed add-backs after QoE diligence<\/a> when those add-backs are properly supported.<\/p>\n<\/li>\n<li>\n<p><strong>Competitive leverage.<\/strong> Because McLerran runs a structured process with multiple vetted buyers, the firm can remind buyers that other qualified bidders are waiting, which reduces the incentive to trade the deal down over marginal disputes.<\/p>\n<\/li>\n<\/ul>\n<p>Soft add-backs, including owner compensation normalization, related-party expenses, and discretionary spending, require documentation and get challenged routinely by buyer QoE teams. Doing that work before the LOI is signed, instead of scrambling during diligence, separates a deal that closes at the agreed value from one that gets renegotiated.<\/p>\n<p><a target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https:\/\/dentaltransitions.com\/contact-us\/\"><strong>Find out how a documented EBITDA analysis would hold up<\/strong> in your own buyer diligence process with a call to McLerran &amp; Associates.<\/a><\/p>\n<h2>Comparing Outcomes: DSO Affiliation Versus Doctor-to-Doctor Sale<\/h2>\n<p>The two transition paths available to most $1.5M-$3M practice owners produce different valuations, deal structures, and post-close experiences. DSO buyers underwrite using normalized EBITDA multiples. Private buyers typically underwrite using SDE multiples or a percentage of collections instead, since these use a different earnings base entirely and can&#8217;t be placed side by side as one metric. The table below compares the other terms of each path.<\/p>\n<table style=\"min-width: 100px;\">\n<colgroup>\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\"><\/colgroup>\n<tbody>\n<tr>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Metric<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>DSO Affiliation<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Doctor-to-Doctor Sale<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Impact on $1.5M-$3M Owner<\/p>\n<\/th>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Typical Headline Multiple Range<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>6x-9x normalized EBITDA<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p><a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/privatepracticeresearch.org\/reports\/how-dental-practices-are-valued-2026\">65-85% of trailing 12-month collections<\/a><\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p><a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/privatepracticeresearch.org\/reports\/how-dental-practices-are-valued-2026\">40-80% DSO premium gap<\/a> on a $2M revenue, 20% EBITDA practice<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Cash at Close<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p><a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/thesorso.com\/answers\/dental-practice-ebitda-multiple\">60-75% of headline value<\/a><\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p><a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/dentalpracticeinsider.org\/dso-vs-private-practice\">80-100% of agreed price<\/a><\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>DSO deals include rollover equity and earnouts that reduce cash at close; private sales pay out more upfront<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Equity &amp; Earnout Components<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>20-35% rollover equity, earnout over 12-36 months<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Minimal; may include a short seller note<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>DSO equity can multiply in a future recapitalization, or lose value if the DSO underperforms<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Post-Close Employment<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Typically 3-5 year employment agreement<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Typically 30-120 day transition work-back<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>DSO suits owners who want to keep practicing; private sale suits those ready to exit sooner<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>McLerran works both paths in roughly equal measure. About 50% of the firm&#8217;s transactions are doctor-to-doctor and 50% are DSO affiliations, which lets the firm build a genuine side-by-side valuation for owners who qualify for either path. That comparison, built on the same CPA-led EBITDA analysis, lets owners choose based on full information rather than a guess.<\/p>\n<h2>Putting It Together Before You Go to Market<\/h2>\n<p>Dental practice EBITDA valuation in 2026 rewards preparation. Owners who arrive with a diligence-grade normalized EBITDA analysis, meaning every add-back documented and hygiene and associate metrics clearly presented, control the narrative that determines what they walk away with. Owners who rely on buyer-set or back-of-the-napkin valuations tend to see that number erode through diligence.<\/p>\n<p>The key takeaways from this guide:<\/p>\n<ul>\n<li>\n<p>Practice Value equals Normalized EBITDA times Market Multiple, and both variables are within the seller&#8217;s influence.<\/p>\n<\/li>\n<li>\n<p>Normalized EBITDA adjusts reported earnings to reflect transferable operating profit under new ownership. It is not the same as net income or SDE.<\/p>\n<\/li>\n<li>\n<p>The most impactful add-backs, meaning owner compensation normalization, personal expenses, family payroll, and one-time costs, require documentation to survive buyer QoE review.<\/p>\n<\/li>\n<li>\n<p>As covered earlier, margins in the 18-28% range remain typical, with hygiene mix and associate coverage as the primary drivers within that range.<\/p>\n<\/li>\n<li>\n<p>DSO affiliations and doctor-to-doctor sales produce different valuations and post-close experiences. The right path depends on the practice&#8217;s profile and the owner&#8217;s goals.<\/p>\n<\/li>\n<li>\n<p>A structured, competitive sale process with multiple vetted buyers can meaningfully increase both the multiple achieved and the terms negotiated.<\/p>\n<\/li>\n<\/ul>\n<p>These outcomes are not theoretical. McLerran &amp; Associates has guided owners through roughly 2,000 successful practice sales totaling approximately $2 billion in closed transaction volume, with a close rate near 85-90%, compared to an industry norm closer to 35-40%. That track record reflects the documentation work described above: a CPA-led EBITDA analysis built to hold up when buyers look under the hood, so the agreed value stays agreed.<\/p>\n<p><a target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https:\/\/dentaltransitions.com\/contact-us\/\"><strong>Discuss your practice and your goals<\/strong> with McLerran &amp; Associates and find out what your normalized EBITDA could be worth in both the private-buyer and DSO markets. Call (512) 900-7989, email info@dentaltransitions.com, or schedule your discovery call online.<\/a><\/p>\n<p>Owners who have not yet decided whether to sell can get the same market data without committing to a process. The <strong>McLerran M&amp;A Summit, October 29-30, 2026<\/strong>, is a dental-only event built for exactly that stage of the decision. Attendees receive 4 CE credits and a complimentary practice valuation worth $2,500, and leave with a clearer picture of deal structures, current EBITDA multiples, and the DSO and private equity landscape.<\/p>\n<h2>Frequently Asked Questions<\/h2>\n<h3>How is normalized EBITDA different from the net income on my tax return?<\/h3>\n<p>Net income on a dental practice tax return is structured to minimize taxable income, which typically understates the practice&#8217;s true earning power for a buyer. Normalized EBITDA starts with that net income figure and adds back interest, taxes, depreciation, and amortization, then resets owner compensation to a market-rate replacement-doctor cost, removes personal expenses run through the practice, and excludes one-time or non-recurring costs. A practice with $300,000 in reported net income might have $500,000 or more in normalized EBITDA once those adjustments are properly documented. At a 7x multiple, that difference represents $1.4 million in enterprise value.<\/p>\n<h3>What EBITDA margin should my dental practice be targeting before I go to market?<\/h3>\n<p>As noted earlier, the 18-28% margin range applies here too. Practices at or above 20% are generally considered investment-grade and tend to draw competitive interest from DSO buyers. Practices below 15% may benefit from pre-market operational improvements, addressing staffing overhead, hygiene productivity, fee schedules, or payer mix, since compressed margins tend to produce compressed offers. If your practice sits below the 20% threshold, a McLerran valuation can identify which specific drivers are suppressing the margin and what a realistic improvement path looks like.<\/p>\n<h3>Why does it matter whether I sell to a DSO or a private buyer from a valuation standpoint?<\/h3>\n<p>The two buyer types use different valuation methods, which can produce very different headline numbers for the same practice. Private buyers typically underwrite on SDE or a percentage of collections, since they are buying both a business and a clinical job for themselves. DSO and private equity buyers underwrite on normalized EBITDA, since they must hire a dentist to replace the seller&#8217;s production. As covered above, this gap can run 40-80% higher under the DSO method for a well-performing practice, though DSO deals usually deliver only 60-75% of that headline as cash at close, with the rest in rollover equity and earnouts. Because McLerran works both paths in roughly equal measure, the firm can model both outcomes side by side so owners compare real after-tax, after-structure economics rather than headline numbers.<\/p>\n<h3>What happens if a buyer&#8217;s Quality of Earnings team challenges my add-backs during diligence?<\/h3>\n<p>A buyer&#8217;s QoE team scrutinizes every normalization adjustment the seller has claimed, testing whether owner compensation was properly benchmarked, whether one-time expenses were truly non-recurring, and whether personal expenses were genuinely personal. Add-backs without documentation are the most common source of deal re-trading, since a buyer reduces the agreed EBITDA figure and that flows directly into a lower purchase price. The defense is preparation. When every add-back is supported by invoices, compensation analyses, or lease comparables before the LOI is signed, the seller&#8217;s team can rebut challenges with evidence instead of assertions. McLerran builds that documentation package as part of the initial valuation, so the numbers are already defended when a buyer&#8217;s QoE team arrives.<\/p>\n<h3>How does McLerran&#8217;s valuation process differ from a free valuation offered by other firms?<\/h3>\n<p>A free valuation is typically a lead-generation tool, a rough estimate designed to start a conversation rather than hold up under buyer scrutiny. When that number anchors a negotiation and then gets challenged in diligence, the deal either re-trades or falls apart. McLerran&#8217;s valuation is a paid, CPA-led engagement that builds the normalized EBITDA figure from the ground up, including remote access to practice management software, cross-referencing against tax returns, and line-by-line add-back documentation. As mentioned in the conclusion, the firm has evaluated more than 10,000 dental practices and closed roughly 2,000 transactions, so the valuation reflects real market data rather than a number designed to win a listing. In one documented case, a free valuation pegged a practice at $2.5 million. McLerran valued it at $4.5 million, and it sold for $5.25 million after a competitive process.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Learn how normalized EBITDA and market multiples can shape your dental practice&#8217;s sale price. Schedule a free discovery call with McLerran today.<\/p>\n","protected":false},"author":1,"featured_media":115,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-116","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/posts\/116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/comments?post=116"}],"version-history":[{"count":0,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/posts\/116\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/media\/115"}],"wp:attachment":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/media?parent=116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/categories?post=116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/tags?post=116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}